Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

0.2045
+0.029516.86%
Post-market: 0.20460.0001+0.05%19:58 EDT
Volume:47.56M
Turnover:9.40M
Market Cap:100.00M
PE:-0.31
High:0.2137
Open:0.1796
Low:0.1681
Close:0.1750
52wk High:3.87
52wk Low:0.1138
Shares:489.00M
Float Shares:301.00M
Volume Ratio:1.20
T/O Rate:15.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6496
EPS(LYR):-0.7455
ROE:-783.37%
ROA:-62.39%
PB:-1.06
PE(LYR):-0.27

Loading ...

Top News Today/Canada: Lululemon Appoints New Board Member; Fourth-Quarter Sales Rise

Dow Jones
·
Mar 18

CORRECTED-Gossamer Bio Q4 net loss widens

Reuters
·
Mar 18

Gossamer Bio Q4 net loss rises 43.01% to USD 47.24 million on R&D expenses up 35.5% to USD 48.94 million

Reuters
·
Mar 18

BRIEF-Gossamer Bio Q4 EPS USD -0.21

Reuters
·
Mar 18

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Mar 18

Gossamer Bio: Pauses Enrollment in Phase 3 Seranata Study in Ph-Ild While Co Evaluates Implications of Prosera Results

THOMSON REUTERS
·
Mar 18

Gossamer Bio: Co Implemented Reduction in Force to Align Resources With Near-Term Priorities

THOMSON REUTERS
·
Mar 18

Gossamer Bio Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Mar 09

Gossamer Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 06

Levi & Korsinsky Investigates Gossamer Bio After PROSERA Phase 3 Trial Misses Endpoint

Reuters
·
Mar 05

Gossamer Bio Faces Investor Lawsuit After Phase 3 PROSERA Trial Miss

Reuters
·
Mar 05

Levi & Korsinsky Probes Gossamer Bio for Possible Securities Fraud

Reuters
·
Mar 04

Gossamer Bio, Inc. : Barclays Cuts to Underweight From Overweight

THOMSON REUTERS
·
Feb 25

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and PepGen Inc. (PEPG)

TIPRANKS
·
Feb 25

NASD Most Active Issues

Dow Jones
·
Feb 25

These Analysts Slash Their Forecasts On Gossamer Bio

Benzinga_recent_news
·
Feb 24

Gossamer Bio Cut to Underweight From Overweight by Barclays

Dow Jones
·
Feb 24

Gossamer Bio Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
Feb 24

Gossamer Bio Shares Down 7.8% Premarket After at Least Two Brokerages Downgrade Stock

THOMSON REUTERS
·
Feb 24

Wedbush Downgrades Gossamer Bio to Neutral From Outperform, Cuts Price Target to $1 From $6

MT Newswires Live
·
Feb 24